Metabolic Brain Disease

, Volume 22, Issue 3–4, pp 389–405

The treatment of hepatic encephalopathy

  • Marsha Y. Morgan
  • A. Blei
  • K. Grüngreiff
  • R. Jalan
  • G. Kircheis
  • G. Marchesini
  • O. Riggio
  • Karin Weissenborn
ORIGINAL PAPER

Abstract

Current recommendations for the treatment of hepatic encephalopathy are based, to a large extent, on open or uncontrolled trials, undertaken in very small numbers of patients. In consequence, there is ongoing discussion as to whether the classical approach to the treatment of this condition, which aims at reducing ammonia production and absorption using either non-absorbable disaccharides and/or antibiotics, should be revisited, modified or even abandoned. Pros and cons of present therapeutic strategies and possible future developments were discussed at the fourth International Hannover Conference on Hepatic Encephalopathy held in Dresden in June 2006. The content of this discussion is summarized.

Keywords

Branched-chain amino acids Bromocriptine Hepatic cirrhosis Hepatic encephalopathy Non-absorbable antibiotics Non-absorbable disaccharides Ornithine aspartate Sodium benzoate Treatment Zinc 

References

  1. Als-Nielsen B, Gluud LL, Gluud C (2004a) Non-absorbable disaccharides for hepatic encephalopathy: systematic review of randomized trials. BMJ 328:1046–1051PubMedCrossRefGoogle Scholar
  2. Als-Nielsen B, Gluud LL, Gluud C (2004b) Non-absorbable disaccharides for hepatic encephalopathy (Cochrane review). In: The Cochrane Library, Issue 2. Wiley, Chichester, UKGoogle Scholar
  3. Als-Nielsen B, Koretz RL, Kjaergard LL, Gluud C (2004c) Branched-chain amino acids for hepatic encephalopathy (Cochrane review). In: The Cochrane Library, Issue 2. Wiley, Chichester, UKGoogle Scholar
  4. Bass NM (2006) The current pharmacological therapies for hepatic encephalopathy. Aliment Pharmacol Ther 25(1):23–31Google Scholar
  5. Bircher J, Müller J, Guggenheim P, Hammerli UP (1966) Treatment of chronic portal systemic encephalopathy with lactulose. Lancet i:890–892Google Scholar
  6. Blanc P, Daures JP, Liautard J, Buttigieg R, Desprez D, Pageaux G et al (1994) Lactulose–neomycin combination versus placebo in the treatment of acute hepatic encephalopathy. Results of a randomized controlled trial. Gastroenterol Clin Biol 18:1063–1068PubMedGoogle Scholar
  7. Blei AT (2004) Infection, inflammation and hepatic encephalopathy, synergism redefined. J Hepatol 40:327–330PubMedCrossRefGoogle Scholar
  8. Canales JJ, Elayadi A, Errami M, Llansola M, Cauli O, Felipo V (2003) Chronic hyperammonemia alters motor and neurochemical responses to activation of group I metabotropic glutamate receptors in the nucleus accumbens in rats in vivo. Neurobiol Dis 14:380–390PubMedCrossRefGoogle Scholar
  9. Chandra RK, McBean LD (1994) Zinc and immunity. Nutrition 10:79–80PubMedGoogle Scholar
  10. Conn HO, Lieberthal MM (1979) The hepatic coma syndromes and lactulose. Williams and Wilkins, BaltimoreGoogle Scholar
  11. Córdoba J, Mínguez B, Vergara M (2005) Treatment of hepatic encephalopathy. Lancet 365:1384–1385PubMedCrossRefGoogle Scholar
  12. Dejong C, Deutz N, Soeters P (1993) Renal ammonia and glutamine metabolism during liver insufficiency-induced hyperammonemia in the rat. J Clin Invest 92:2834–2840PubMedCrossRefGoogle Scholar
  13. Dragon Y, Avraham Y, Ilan Y, Mechoulam R, Berry EM (2007) Cannabinoids ameliorate cerebral dysfunction following liver failure via AMP-activated protein kinase. FASEB J (in press)Google Scholar
  14. Erceg S, Monfort P, Hernandez-Viadel M, Rodrigo R, Montoliu C, Felipo V (2005) Oral administration of sidenafil restore learning ability in rats with hyperammonemia and with portacaval shunts. Hepatology 41:299–306PubMedCrossRefGoogle Scholar
  15. Fleig WE, Kircheis G, Spengler U, Zeuzem St, Görtelmeyer R, German–Austrian–Swiss Multicentre Study Group (1999) Placebo-controlled, double-blind evaluation of l-ornithine–l-aspartate (LOLA) granules in patients with cirrhosis and subclinical (SHE) or mild overt hepatic encephalopathy (HE). J Hepatol 30(1):65CrossRefGoogle Scholar
  16. Grüngreiff K, Presser HJ, Franke D, Lössner B, Abicht K, Kleine FD (1989) Correlations between zinc, amino acids and ammonia in liver cirrhosis. Z Gastroenterol 27:731–735PubMedGoogle Scholar
  17. Grüngreiff K, Grüngreiff S, Reinhold D (2000) Zinc deficiency and hepatic encephalopathy. Results of a long-term zinc supplementation. Trace Elem Exp Med 13:21–31CrossRefGoogle Scholar
  18. Henglein-Ottermann D (1976) Der Einfluβ von Ornithin-Aspartat auf die Experimentell erzeugte Hyperammoniämie. Klinisch-experimentelle Studie. Therapie der Gegenwart 115:1504–1518PubMedGoogle Scholar
  19. Ishiki Y, Ohnishi H, Muto Y, Matsumoto K, Nakamura T (1992) Direct evidence that hepatocyte growth factor is a hepatotrophic factor for liver regeneration and has a potent antihepatitis effect in vivo. Hepatology 16:1227–1235PubMedGoogle Scholar
  20. Iwasa M, Matsumura K, Watanabe Y, Yamamoto M, Kaito M, Ikoma J et al (2003) Improvement of regional cerebral blood flow after treatment with branched-chain amino acid solutions in patients with cirrhosis. Eur J Gastroenterol Hepatol 15:733–737PubMedCrossRefGoogle Scholar
  21. Jalan R, Kapoor D (2004) Reversal of diuretic-induced hepatic encephalopathy with infusion of albumin but not colloid. Clin Sci 106:467–474PubMedCrossRefGoogle Scholar
  22. Jalan R, Wright G, Davies NA, Hodges SJ (2007) L-ornithine-phenylacetate (OP): A novel treatment for hyperammonemia and hepatic encephalopathy. Med Hypotheses (in press)Google Scholar
  23. Kale RA, Gupta RK, Saraswat VA, Hasan KM, Trivedi R, Mishra AM et al (2006) Demonstration of interstitial cerebral edema with diffusion tensor MR imaging in type C hepatic encephalopathy. Hepatology 43:698–706PubMedCrossRefGoogle Scholar
  24. Kalk H (1958) Die Klinik der akuten Leberinsuffizienz. Gastroenterologia 90:271–290PubMedCrossRefGoogle Scholar
  25. Katayama K (2004) Ammonia metabolism and hepatic encephalopathy. Hepatol Res 30S:S71–S78Google Scholar
  26. Kircheis G, Metz M, Frey S, Seiller E (1996) Correlation between pharmacokinetic aspects and clinical efficacy of l-ornithine–l-aspartate (OA): results of randomized, controlled clinical trials. J Hepatol 25(1):131Google Scholar
  27. Kircheis G, Nilius R, Held C, Berndt H, Buchner M, Gortelmeyer R et al (1997) Therapeutic efficacy of l-ornithine–l-aspartate infusions in patients with cirrhosis and hepatic encephalopathy: Results of a placebo-controlled double-blind study. Hepatology 25:1351–1360PubMedCrossRefGoogle Scholar
  28. Kunin CM, Chalmers TC, Leevy CM, Sebastyen SC, Lieber CS, Finland M (1960) Absorption of orally administered neomycin and kanamycin with special reference to patients with severe hepatic and renal disease. N Engl J Med 262:380–385PubMedCrossRefGoogle Scholar
  29. Lai D, Gorbach SL, Levitan R (1972) Intestinal microflora in patients with alcoholic cirrhosis: urea-splitting bacteria and neomycin resistance. Gastroenterology 62:275–279PubMedGoogle Scholar
  30. Lanthier PL, Morgan MY, Ballantyne J (1984) Bromocriptine-associated ototoxicity. J Laryngol Otol 98:399–404PubMedGoogle Scholar
  31. Leevy CB, Phillips JA (2007) Hospitalizations during the use of rifaximin versus lactulose for the treatment of hepatic encephalopathy. Dig Dis Sci 52:737–741PubMedCrossRefGoogle Scholar
  32. Leonhardt H, Bungert HJ (1972) Therapie der schweren Hyperammoniämie. Med Klin 67:1052–1056PubMedGoogle Scholar
  33. Lighthouse J, Naito Y, Helmy A, Hotten P, Fuji H, Min CH et al (2004) Endotoxinemia and benzodiazepine-like substances in compensated cirrhotic patients: A randomized study comparing the effect of rifaximine alone and in association with a symbiotic preparation. Hepatol Res 28:155–160PubMedCrossRefGoogle Scholar
  34. Liu Q, Duan ZP, Ha DK, Bengmark S, Kurtovic J, Riordan SM (2004) Synbiotic modulation of gut flora: effect on minimal hepatic encephalopathy in patients with cirrhosis. Hepatology 39:1441–1449PubMedCrossRefGoogle Scholar
  35. Loguercio C, Abbiati R, Rinaldi M, Romano A, Del Vecchio Blanco C, Coltorti M (1995) Long-term effects of Enterococcus faecium SF68 versus lactulose in the treatment of patients with cirrhosis and grade 1–2 hepatic encephalopathy. J Hepatol 23:39–46CrossRefGoogle Scholar
  36. Loguercio C, Federico A, Tuccillo C, Terracciano F, D’Auria MV, De Simone C et al (2005) Beneficial effects of a probiotic VSL#3 on parameters of liver dysfunction in chronic liver diseases. J Clin Gastroenterol 39:540–543CrossRefGoogle Scholar
  37. Macbeth WA, Kass EH, McDermott WV Jr (1965) Treatment of hepatic encephalopathy by alteration of intestinal flora with Lactobacillus acidophilus. Lancet 191:399–403CrossRefGoogle Scholar
  38. Malaguarnera M, Pistone G, Elivra R, Leotta C, Scarpello L, Liborio R (2005) Effect of l-carnitine in patients with hepatic encephalopathy. World J Gastroenterol 11:7197–7202PubMedGoogle Scholar
  39. Marchesini G, Fabr A, Bianchi G, Brizi M, Zoloi M (1996) Zinc supplementation and amino-acid nitrogen-metabolism in patients with advanced cirrhosis. Hepatology 23:1084–1092PubMedCrossRefGoogle Scholar
  40. Marchesini G, Bianchi G, Merli M, Amodio P, Panella C, Loguercio C et al (2003) Nutritional supplementation with branched-chain amino acids in advanced cirrhosis: a double-blind, randomized trial. Gastroenterology 124:1792–1801PubMedCrossRefGoogle Scholar
  41. Marshall AW, Jakobovits AW, Morgan MY (1982) Bromocriptine-associated hyponatraemia in cirrhosis. BMJ 285:1534–1535PubMedGoogle Scholar
  42. Mas A, Rodes J, Sunyer L, Rodrigo L, Planas R, Vargas V et al , Spanish Association for the Study of the Liver Hepatic Encephalopathy Cooperative Group (2003) Comparison of rifaximin and lactitol in the treatment of acute hepatic encephalopathy: Results of a randomized, double-blind, double-dummy, controlled clinical trial. J Hepatol 38:51–58PubMedCrossRefGoogle Scholar
  43. Matsuda I, Ohtani Y, Ohyanagi K, Yamamoto S (1987) Hyperammonemia related to carnitine metabolism with particular emphasis on ornithine transcarbamylase deficiency. Enzyme 38:251–255PubMedGoogle Scholar
  44. Morgan MY, Hawley KE (1987) Lactitol versus lactulose in the treatment of acute hepatic encephalopathy in cirrhotic patients: a double-blind, randomized trial. Hepatology 7:1278–1284PubMedCrossRefGoogle Scholar
  45. Morgan MY, Jakobovits AW, James IM, Sherlock S (1980) Successful use of bromocriptine in the treatment of chronic hepatic encephalopathy. Gastroenterology 78:663–670PubMedGoogle Scholar
  46. Morgan MY, Alonso M, Stanger LC (1989) Lactitol and lactulose for the treatment of subclinical hepatic encephalopathy in cirrhotic patients. J Hepatol 8:208–217PubMedCrossRefGoogle Scholar
  47. Muto Y, Sato S, Watanabe A, Moriwaki H, Suzuki K, Kato A et al (2005) Effects of oral branched-chain amino acid granules on event-free survival in patients with liver cirrhosis. Clin Gastroenterol Hepatol 3:705–713PubMedCrossRefGoogle Scholar
  48. Neff GW, Kemmer N, Zacharias VC, Kaiser T, Duncan C, McHenry R et al (2006) Analysis of hospitalizations comparing rifaximin versus lactulose in the management of hepatic encephalopathy. Transplant Proc 38:3552–3555PubMedCrossRefGoogle Scholar
  49. Olde Damink SW, Deutz N, Redhead D, Hayes P, Soeters P, Jalan R (2002) Interorgan ammonia and amino acid metabolism in metabolically stable patients with cirrhosis and a TIPSS. Hepatology 36:1163–1171PubMedCrossRefGoogle Scholar
  50. Olde Damink SW, Jalan R, Deutz NE, Redhead DN, Dejong CH, Hynd P et al (2003) The kidney plays a major role in the hyperammonemia seen after simulated or actual GI bleeding in patients with cirrhosis. Hepatology 37:1277–1285PubMedCrossRefGoogle Scholar
  51. Pedretti G, Calzetti C, Missale G, Fiaccadori F (1991) Rifaximin versus neomycin on hyperammoniemia in chronic portal systemic encephalopathy in cirrhotics. A double-blind, randomized trial. Ital J Gastroenterol 23:175–178PubMedGoogle Scholar
  52. Poo JL, Gongora J, Sanchez-Avila F, Aguilar-Castillo S, Garcia-Ramos G, Fernandez-Zertuche M et al (2006) Efficacy of oral l-ornithine–l-aspartate in cirrhotic patients with hyperammonemic hepatic encephalopathy. Results of a randomized, lactulose-controlled study. Ann Hepatol 5:281–288PubMedGoogle Scholar
  53. Prasad AS, Rabbani P, Abasi A, Bowersox E (1978) Experimental zinc deficiency. Ann Intern Med 89:483–490PubMedGoogle Scholar
  54. Prasad S, Dhiman RK, Duseja A, Chawla YK, Sharma A, Agarwal R (2007) Lactulose improves cognitive function and health-related quality of life in patients with cirrhosis who have minimal hepatic encephalopathy. Hepatology 45:549–559PubMedCrossRefGoogle Scholar
  55. Rabbani P, Prasad AS (1978) Plasma ammonia and liver ornithine carbamoyltransferase activity in zinc deficient rats. Am J Physiol 235:E203–E206PubMedGoogle Scholar
  56. Raskind JY, El-Chaar GM (2000) The role of carnitine supplementation during valproic acid therapy. Ann Pharmacother 34:630–638PubMedCrossRefGoogle Scholar
  57. Reding P, Duchateau J, Bataille C (1984) Oral zinc supplementation improves hepatic encephalopathy. Results of a randomized controlled trial. Lancet 2:493–494PubMedCrossRefGoogle Scholar
  58. Rees CJ, Oppong K, Al Mardini H, Hudson M, Record CO (2000) Effect of l-ornithine–l-aspartate on patients with and without TIPS undergoing glutamine challenge: a double blind, placebo controlled trial. Gut 47:571–574PubMedCrossRefGoogle Scholar
  59. Riggio O, Ariosto F, Merli M, Caschera M, Zullo A, Balducci G et al (1991) Short-term oral zinc supplementation does not improve chronic hepatic encephalopathy. Results of a double-blind crossover trial. Dig Dis Sci 36:1204–1208PubMedCrossRefGoogle Scholar
  60. Riggio O, Merli M, Capocaccia L, Caschera M, Zullo A, Pinto G et al (1992) Zinc supplementation reduces blood ammonia and increases liver transcarbamylase activity in experimental cirrhosis. Hepatology 16:785–789PubMedCrossRefGoogle Scholar
  61. Romero-Gómez M, Ramos-Guerrero R, Grande L, de Terán LC, Corpus R, Camacho I et al (2004) Intestinal glutaminase activity is increased in liver cirrhosis and correlates with minimal hepatic encephalopathy. J Hepatol 41:49–54PubMedCrossRefGoogle Scholar
  62. Rössle M, Nasari I, Ochs A, Haag K (1997) Effekt einer Zinksubstitution auf die Ammoniakkonzentration und die hepatische Enzephalopathie bei Patienten mit Zirrhose und Shunt. Z Gastroenterol 35(96):A155Google Scholar
  63. Schölmerich J (1987) Zinc and vitamin A in liver cirrhosis. In: Boyer JL, Bianchi L (eds) Liver cirrhosis. MTP, Lancaster, pp 421–432Google Scholar
  64. Shawcross D, Jalan R (2005) Dispelling myths in the treatment of hepatic encephalopathy. Lancet 365:431–433PubMedGoogle Scholar
  65. Shawcross DL, Davies NA, Williams R, Jalan R (2004) Systemic inflammatory response exacerbates the neuropsychological effects of induced hyperammonaemia in cirrhosis. J Hepatol 40:247–254PubMedCrossRefGoogle Scholar
  66. Shawcross DL, Wright G, Olde Damink SWM, Jalan R (2007) Role of ammonia and inflammation in minimal hepatic encephalopathy. Met Brain Dis 22:125–138CrossRefGoogle Scholar
  67. Staedt U, Leweling H, Gladisch R, Kortsik C, Hagmuller E, Holm E (1993) Effects of ornithine aspartate on plasma ammonia and plasma amino acids in patients with cirrhosis. A double-blind, randomized study using a four-fold crossover design. J Hepatol 19:424–430PubMedCrossRefGoogle Scholar
  68. Stauch S, Kircheis G, Adler G, Beckh H, Ditschuneit H, Görtelmeyer R (1998) Oral l-ornithine–l-aspartate therapy of chronic hepatic encephalopathy: results of a placebo-controlled double-blind study. J Hepatol 28:856–864PubMedCrossRefGoogle Scholar
  69. Strauss E, Tramote R, Silva EP, Caly WR, Honain NZ, Maffei RA et al (1992) Double-blind randomized clinical trial comparing neomycin and placebo in the treatment of exogenous hepatic encephalopathy. Hepatogastroenterology 39:542–545PubMedGoogle Scholar
  70. Sushma S, Dasarathy S, Tandon RK, Jain S, Gupta S, Bhist MS (1992) Sodium benzoate in the treatment of acute hepatic encephalopathy: a double-blind randomized trial. Hepatology 16:138–144PubMedCrossRefGoogle Scholar
  71. Tomiya T, Inoue Y, Yanase M, Arai M, Ikeda H, Tejima K et al (2002) Leucine stimulates the secretion of hepatocyte growth factor by hepatic stellate cells. Biochem Biophys Res Commun 297:1108–1111PubMedCrossRefGoogle Scholar
  72. Uribe M, Rampollo O, Vargas F, Ravelli GP, Mundo F, Zapata L et al (1987) Acidifying enemas (lactitol and lactose) vs. nonacidifying enemas (tap water) to treat acute portal-systemic encephalopathy: a double-blind randomized clinical trial. Hepatology 7:639–643PubMedCrossRefGoogle Scholar
  73. Van der Rijt C, Schalm SW, Han S, Foelen K, De Jong G (1991) Overt hepatic encephalopathy precipitated by zinc deficiency. Gastroenterology 100:1114–1118PubMedGoogle Scholar
  74. van Leeuwen PA, van Berlo CL, Soeters PB (1988) New mode of action for lactulose. Lancet i:55–56CrossRefGoogle Scholar
  75. Yamamoto M, Iwasa M, Matsumura K, Nakagawa Y, Fujita N, Kobayashi Y et al (2005) Improvement of regional cerebral blood flow after oral intake of branched-chain amino acids in patients with cirrhosis. World J Gastroenterol 11:6792–6799PubMedGoogle Scholar
  76. Yoshida Y, Higashi T, Nouso K, Nakatsukasa H, Nakamura S, Watanabe A et al (2001) Effects of zinc deficiency/zinc supplementation on ammonia metabolism in patients with decompensated liver cirrhosis. Acta Med Okayama 55:349–355PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  • Marsha Y. Morgan
    • 1
  • A. Blei
    • 2
  • K. Grüngreiff
    • 3
  • R. Jalan
    • 4
  • G. Kircheis
    • 5
  • G. Marchesini
    • 6
  • O. Riggio
    • 7
  • Karin Weissenborn
    • 8
  1. 1.Centre for Hepatology, Division of MedicineRoyal Free Campus, Royal Free and University College Medical School, University College LondonLondonUK
  2. 2.Northwestern UniversityChicagoUSA
  3. 3.Hepatology Outpatient PracticeMagdeburgGermany
  4. 4.Institute of Hepatology, Division of MedicineBloomsburg Campus, Royal Free and University College Medical School, University College LondonLondonUK
  5. 5.Department of Gastroenterology, Hepatology and InfectiologyHeinrich-Heine-UniversityDüsseldorfGermany
  6. 6.Unit of Clinical DieteticsAlma Mater Studiorum UniversityBolognaItaly
  7. 7.Department of Clinical Medicine, Division of GastroenterologyUniversity of Rome La SapienzaRomeItaly
  8. 8.Department of NeurologyMedical School HannoverHannoverGermany

Personalised recommendations